All In Biotech

Drug Trial Radar · NCT02677298

Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo, Followed by an Open Label Extension Study

Last checked: Nov 20, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 784 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

784

Actual

Start

Mar 2, 2016

Primary completion

Nov 23, 2016

Study completion Nov 16, 2017

Sponsor

Lead sponsor
Croma-Pharma GmbHIndustry
Sponsor type
Industry
First posted
Feb 9, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The aim of this study is to assess the efficacy and safety of BoNT/A-DP in the treatment of glabellar lines in comparison with placebo, including efficacy after repeat treatments and long term safety.

Conditions

  • Glabellar Frown Lines

Interventions

  • Botulinum Toxin ADrug

    Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.

  • PlaceboDrug

    Injection, 0.9% sodium chloride divided in five 0.1 mL i.m. injections into glabellar area

  • Botulinum Toxin ADrug

    Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area in up to 3 treatment cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the Investigators´ and the Subjects´ In-clinic Assessments.Time frame: Week 4

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Total Skin And Beauty Dermatology Center, Pc

    Birmingham, Alabama

  • Clinical Testing of Beverly Hills

    Encino, California

  • Maas Clinic

    San Francisco, California

  • About Skin

    Greenwood Village, Colorado

  • DeNova Research

    Chicago, Illinois

  • Skin Specialists

    Omaha, Nebraska

  • Aesthetic Solutions

    Chapel Hill, North Carolina

  • Society Hill Dermatology

    Philadelphia, Pennsylvania

  • Tennessee Clinical Research Center

    Nashville, Tennessee

  • RZANY & HUND, Privatpraxis

    Berlin, Germany

  • S-thetic Clinic Hamburg

    Hamburg, Germany

  • Praxis Klinik Dr. Med. Anita Ruetter

    Münster, Germany

  • Praxisklinik Fur Dermatologie, Hautzentrum am Starnberger See

    Starnberg, Bavaria, Germany

  • Rosenpark Research

    Darmstadt, Hesse, Germany

  • Carpe Diem, Centre for Aesthetic Medicine

    Warsaw, Poland

  • Clinical Research Group Sp. z o.o.

    Warsaw, Poland

  • Estederm Dr Marcin Ambroziak

    Warsaw, Poland

  • High-Med. Przychodnia Specjalistyczna

    Warsaw, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.